A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients
Latest Information Update: 19 Dec 2025
At a glance
- Drugs Cyclophosphamide (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 12 Dec 2025 Actual Primary Completion date changed to 8 Dec 2025.
- 12 Dec 2025 Status changed from active, no longer recruiting to completed.
- 30 Jul 2024 Planned End Date changed from 20 Nov 2026 to 1 Nov 2025.